Case number 2019-2400
IBSA Institut Biochimique v. Teva Pharmaceuticals USA > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Oct 4, 2021 | 0 | IBSA INSTITUT BIOCHIMIQUE v. TEVA PHARMACEUTICALS USA [OPINION] [precedential] (0) |
| Apr 5, 2021 | 47 | The petition for writ of certiorari, No. 20-1232, filed on 03/01/2021, was Denied on 04/05/2021. [766852] [JCP] [Entered: 04/06/2021 09:07 AM] (1) |
| Mar 9, 2021 | 46 | Petition for writ of certiorari filed on 03/01/2021 in the U.S. Supreme Court. No.: 20-1232, S.A. IBSA Institut Biochimique v. Inc. Teva Pharmaceuticals USA. [761256] [JCP] [Entered: 03/09/2021 05:07 PM] (1) |
| Oct 9, 2020 | 45 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [727805] [JAB] [Entered: 10/09/2020 09:31 AM] (1) |
| Oct 2, 2020 | 44 | ORDER filed denying combined petition for panel rehearing and rehearing en banc [43] filed by IBSA Institut Biochimique, S.A., Altergon, S.A. and IBSA Pharma Inc. By: Per Curiam. Service as of this date by the Clerk of Court. [726083] [MJL] [Entered: 10/02/2020 10:26 AM] (2) |
| Aug 31, 2020 | 43 | Petition for panel rehearing, for en banc rehearing filed by Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc.. Service: 08/31/2020 by email. [718612] [19-2400] [Jeffrey Oelke] [Entered: 08/31/2020 05:09 PM] (38) |
| Jul 31, 2020 | 42 | JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [711541] [JAB] [Entered: 07/31/2020 10:13 AM] (1) |
| Jul 31, 2020 | 41 | OPINION filed for the court by Prost, Chief Judge; Reyna, Circuit Judge and Hughes, Circuit Judge. Precedential Opinion. [711540] [JAB] [Entered: 07/31/2020 10:12 AM] (13) |
| May 6, 2020 | 40 | Submitted after ORAL ARGUMENT by Ryan Johnson for IBSA Institut Biochimique, S.A., Altergon, S.A. and IBSA Pharma Inc. and Mr. John Christopher Rozendaal for Teva Pharmaceuticals USA, Inc. Panel: Judge: Prost , Judge: Reyna , Judge: Hughes. [692517] [JCP] [Entered: 05/06/2020 10:56 AM] (0) |
| Apr 21, 2020 | 39 | Clerk's Letter to Appellants Altergon, S.A., IBSA Institut Biochimique, S.A., IBSA Pharma Inc. and Appellee Teva Pharmaceuticals USA, Inc. (May 2020 Telephonic Argument Orientation). Service as of this date by the Clerk of Court. [688886] [JBP] [Entered: 04/21/2020 04:17 PM] (0) |
| Apr 20, 2020 | 38 | ORDER filed. The court will conduct argument in this case by telephone at the originally scheduled date and time in lieu of in-person appearance. The Clerk's Office will provide additional instructions to counsel at least one week ahead of argument. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [688363] [JAB] [Entered: 04/20/2020 02:55 PM] (2) |
| Apr 14, 2020 | 37 | Response to notice of oral argument from the Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc.. [686908] [19-2400] [Jeffrey Oelke] [Entered: 04/14/2020 04:08 PM] (3) |
| Apr 10, 2020 | 36 | Response to notice of oral argument from the Appellee Teva Pharmaceuticals USA, Inc.. [686061] [19-2400] [John Rozendaal] [Entered: 04/10/2020 02:56 PM] (3) |
| Mar 20, 2020 | 35 | NOTICE OF ORAL ARGUMENT. Panel: 2005H. Case scheduled May 6, 2020 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 402. Response to Notice of Oral Argument due: 04/15/2020. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [680468] [JAB] [Entered: 03/20/2020 11:29 AM] (2) |
| Mar 16, 2020 | 34 | The following conflict dates submitted by John Christopher Rozendaal for Teva Pharmaceuticals USA, Inc. have been accepted by the court: 10/05/2020, 10/06/2020, 10/07/2020, 10/08/2020, 10/09/2020. [678854] [JAB] [Entered: 03/16/2020 08:09 AM] (0) |
| Mar 13, 2020 | 33 | Notice from Appellee Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument. Service: 03/13/2020 by email. [678779] [19-2400] [John Rozendaal] [Entered: 03/13/2020 05:49 PM] (3) |
| Mar 13, 2020 | 32 | Notice from Appellants IBSA Institut Biochimique, S.A., Altergon, S.A. and IBSA Pharma Inc. regarding conflicts with oral argument. None. Service: 03/13/2020 by email. [678609] [19-2400] [Jeffrey Oelke] [Entered: 03/13/2020 12:38 PM] (2) |
| Mar 12, 2020 | 31 | 6 paper copies of the Opening Brief [16] received from Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc. [678488] [CJF] [Entered: 03/13/2020 09:56 AM] (0) |
| Mar 11, 2020 | 30 | 6 paper copies of the Joint Appendix [20] received from Appellants Altergon, S.A., IBSA Institut Biochimique, S.A., IBSA Pharma Inc. and Appellee Teva Pharmaceuticals USA, Inc. [677904] [CJF] [Entered: 03/11/2020 01:46 PM] (0) |
| Mar 11, 2020 | 28 | 6 paper copies of the Reply Brief [19] received from Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc. [677831] [CJF] [Entered: 03/11/2020 11:43 AM] (0) |
| Mar 10, 2020 | 29 | 6 paper copies of the Opening Response Brief [18] received from Appellee Teva Pharmaceuticals USA, Inc. [677833] [CJF] [Entered: 03/11/2020 11:44 AM] (0) |
| Mar 9, 2020 | 27 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(1). [677264] [JAB] [Entered: 03/09/2020 02:41 PM] (0) |
| Mar 9, 2020 | 26 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [677259] [JAB] [Entered: 03/09/2020 02:38 PM] (1) |
| Feb 17, 2020 | 24 | Notice to counsel for Appellants Altergon, S.A., IBSA Institut Biochimique, S.A., and IBSA Pharma Inc.: The record of this case indicates that the Corrected Transcript Purchase Order Form has not been filed. Service as of this date by the Clerk of Court. [671791] [JAL] [Entered: 02/17/2020 12:57 PM] (0) |
| Feb 17, 2020 | 25 | Transcript Purchase Order Form for the Appellants IBSA Institut Biochimique, S.A., IBSA Pharma Inc. and Altergon, S.A. indicating that a transcript is already on file. Service: 02/17/2020 by email. [671826] [19-2400] [Laura Moran] [Entered: 02/17/2020 04:46 PM] (2) |
| Jan 23, 2020 | 23 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellee Teva Pharmaceuticals USA, Inc.. Service: 01/23/2020 by email. [665702] [19-2400] [John Rozendaal] [Entered: 01/23/2020 09:33 PM] (3) |
| Jan 23, 2020 | 22 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc.. Service: 01/23/2020 by email. [665679] [19-2400] [Jeffrey Oelke] [Entered: 01/23/2020 05:06 PM] (3) |
| Jan 23, 2020 | 21 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellants Altergon, S.A., IBSA Institut Biochimique, S.A., IBSA Pharma Inc. and Appellee Teva Pharmaceuticals USA, Inc.. Service: 01/23/2020 by email. [665677] [19-2400] [Jeffrey Oelke] [Entered: 01/23/2020 05:04 PM] (3) |
| Jan 23, 2020 | 20 | MODIFIED ENTRY: JOINT APPENDIX FILED for Appellants Altergon, S.A., IBSA Institut Biochimique, S.A., and IBSA Pharma Inc., and Appellee Teva Pharmaceuticals USA, Inc. Number of Pages: 433. Service: 01/23/2020 by email. [665675] --[Edited 02/20/2020 by JAL - Compliance review complete] [Jeffrey Oelke] [Entered: 01/23/2020 05:02 PM] (433) |
| Jan 16, 2020 | 19 | MODIFIED ENTRY: REPLY BRIEF FILED for Appellants Altergon, S.A., IBSA Institut Biochimique, S.A., and IBSA Pharma Inc. Number of Pages: 35. Service: 01/16/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [663894] --[Edited 02/19/2020 by JAL - Compliance review complete] [Jeffrey Oelke] [Entered: 01/16/2020 03:10 PM] (44) |
| Dec 26, 2019 | 18 | MODIFIED ENTRY: RESPONSE BRIEF FILED for Appellee Teva Pharmaceuticals USA, Inc. Number of Pages: 51. Service: 12/26/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [658930] --[Edited 02/17/2020 by JAL - Compliance review complete] [John Rozendaal] [Entered: 12/26/2019 02:58 PM] (59) |
| Nov 21, 2019 | 17 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a) and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [651371] [JAL] [Entered: 11/21/2019 03:13 PM] (0) |
| Nov 15, 2019 | 16 | MODIFIED ENTRY: OPENING BRIEF FILED for Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc. Number of Pages: 70. Service: 11/15/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [649759] --[Edited 11/21/2019 by JAL - Compliance review complete] [Jeffrey Oelke] [Entered: 11/15/2019 05:30 PM] (115) |
| Sep 30, 2019 | 15 | Entry of appearance for Ryan P. Johnson as of counsel for Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc.. Service: 09/30/2019 by email. [639201] [19-2400] [Ryan Johnson] [Entered: 09/30/2019 04:56 PM] (2) |
| Sep 30, 2019 | 14 | Entry of appearance for Erica R. Sutter as of counsel for Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc.. Service: 09/30/2019 by email. [639199] [19-2400] [Erica Sutter] [Entered: 09/30/2019 04:52 PM] (2) |
| Sep 30, 2019 | 13 | Entry of appearance for Laura T. Moran as of counsel for Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc.. Service: 09/30/2019 by email. [639195] [19-2400] [Laura Moran] [Entered: 09/30/2019 04:46 PM] (2) |
| Sep 30, 2019 | 12 | Entry of appearance for Jeffrey J. Oelke as principal counsel for Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc.. Service: 09/30/2019 by email. [639190] [19-2400] [Jeffrey Oelke] [Entered: 09/30/2019 04:40 PM] (2) |
| Sep 30, 2019 | 11 | Certificate of Interest for Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc.. Service: 09/30/2019 by email. [639184] [19-2400] [Jeffrey Oelke] [Entered: 09/30/2019 04:31 PM] (3) |
| Sep 30, 2019 | 10 | Docketing Statement for the Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc.. Service: 09/30/2019 by email. [639176] [19-2400] [Jeffrey Oelke] [Entered: 09/30/2019 04:23 PM] (3) |
| Sep 30, 2019 | 9 | Entry of appearance for Deirdre M. Wells as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 09/30/2019 by email. [639082] [19-2400] [Kristina Caggiano Kelly] [Entered: 09/30/2019 01:24 PM] (2) |
| Sep 30, 2019 | 8 | Entry of appearance for Kristina Caggiano Kelly as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 09/30/2019 by email. [639080] [19-2400] [Kristina Caggiano Kelly] [Entered: 09/30/2019 01:23 PM] (2) |
| Sep 30, 2019 | 7 | Entry of appearance for Michael E. Joffre as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 09/30/2019 by email. [639078] [19-2400] [Michael Joffre] [Entered: 09/30/2019 01:21 PM] (2) |
| Sep 30, 2019 | 6 | Docketing Statement for the Appellee Teva Pharmaceuticals USA, Inc.. Service: 09/30/2019 by email. [639077] [19-2400] [John Rozendaal] [Entered: 09/30/2019 01:19 PM] (4) |
| Sep 30, 2019 | 5 | Certificate of Interest for Appellee Teva Pharmaceuticals USA, Inc.. Service: 09/30/2019 by email. [639075] [19-2400] [John Rozendaal] [Entered: 09/30/2019 01:18 PM] (3) |
| Sep 30, 2019 | 4 | Entry of appearance for John Christopher Rozendaal as principal counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 09/30/2019 by email. [639073] [19-2400] [John Rozendaal] [Entered: 09/30/2019 01:17 PM] (2) |
| Sep 24, 2019 | 3 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Altergon, S.A., IBSA Institut Biochimique, S.A., and IBSA Pharma Inc., Transcript Purchase Order Form [2], is not in compliance with the rules of this court (see attached). Compliant document is due on 10/01/2019. Service as of this date by the Clerk of Court. [637827] [JAL] [Entered: 09/24/2019 02:29 PM] (2) |
| Sep 23, 2019 | 2 | Transcript Purchase Order Form for the Appellants Altergon, S.A., IBSA Institut Biochimique, S.A. and IBSA Pharma Inc. indicating that a transcript is already on file. Service: 09/23/2019 by email. [637590] [19-2400] This document is non-compliant. See Doc No.[3] [Laura Moran] [Entered: 09/23/2019 05:00 PM] (1) |
| Sep 16, 2019 | 1 | Appeal docketed. Received: 09/10/2019. [635668]Entry of Appearance due 09/30/2019. Certificate of Interest is due on 09/30/2019. Docketing Statement due 09/30/2019. Appellants' brief is due 11/15/2019. [TAM] [Entered: 09/16/2019 11:01 AM] (40) |
